RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Dermatomyositis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
[A case of idiopathic orbital myositis presenting with acute-onset left blepharoptosis].
Sugiyama Ryota et al., Rinsho shinkeigaku = Clinical neurology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893878/
- 2.
Anti-Ro52/TRIM21 seropositivity in interstitial lung disease: effect modification by disease subtype and myositis-specific antibody context
Junfeng Su et al., Frontiers in Immunology (16 October 2026)
https://doi.org/10.3389/fimmu.2026.1960409
- 3.
Interstitial lung disease and mortality in anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis (registration protocol)
Hengpu Ren, Zenodo (CERN European Organization for Nuclear Research) (16 October 2026)
https://doi.org/10.5281/zenodo.23418568
- 4.
Outcomes of systemic sclerosis with overlapping myositis: a propensity score-matched cohort study.
Minikumari Rahulan Lekshmi et al., Rheumatology (Oxford, England) (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886520/
- 5.
Dermatomyositis with Acute Motor-Sensory Axonal Neuropathy Variant of Guillain-Barré Syndrome: A Rare Coexistence
, International Journal of Drug Delivery Technology (14 October 2026)
https://doi.org/10.25258/ijddt.16.67s.87
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417 · Recruiting · Phase 1 · Chugai Pharmaceutical
Ages 18 to 85
https://clinicaltrials.gov/study/NCT06371417
- 2.
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449 · Recruiting · Phase 3 · AstraZeneca
Ages 18 to 75
https://clinicaltrials.gov/study/NCT06455449
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Dermatomyositis
Dermatomyositis is a rare autoimmune condition causing muscle inflammation and weakness, accompanied by characteristic skin rashes. It is part of the inflammatory myopathy group. It can be associated with internal cancers in adults. Immunosuppressive therapy is the main treatment, with newer biologic agents showing promise.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Dermatomyositis?
Dermatomyositis is a rare autoimmune condition causing muscle inflammation and weakness, accompanied by characteristic skin rashes. It is part of the inflammatory myopathy group. It can be associated with internal cancers in adults. Immunosuppressive therapy is the main treatment, with newer biologic agents showing promise.
How many clinical trials are available for Dermatomyositis?
RareWays currently indexes 190 clinical trials for Dermatomyositis, of which 48 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Dermatomyositis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Dermatomyositis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.